Osteocyte Control of Bone Remodeling
Osteocyte Control of Bone Remodeling
批准号:
8880756
负责人:
CHARLES A O'BRIEN
金额:
$32.78万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-29 至 2020-03-31
关键词:
AddressAdultAgingAllelesBindingBone MatrixBone ResorptionBone remodelingCellsCleaved cellCommunicationCytokine ReceptorsFibroblast Growth FactorGenerationsGenesGenotypeGlucocorticoidsGoalsHistologicHyperparathyroidismIntegral Membrane ProteinLigandsMeasuresMechanicsMembraneMusOsteoclastsOsteocytesParathyroid Hormone ReceptorPeptide HydrolasesPhenotypePhysiologicalPorosityProcessProductionProteinsResistanceSkeletonSourceStructureTNFSF11 geneTransgenic MiceTumor necrosis factor receptor 11bbasebonebone lossbone masscell typecytokinedentin matrix protein 1normal agingprogenitorpublic health relevancereceptorskeletaltherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The overall goal of this project is to understand how osteocytes, cells embedded in the bone matrix, control the process of bone resorption by osteoclasts under physiological and pathological conditions. Osteoclast formation, function, and survival depend on the cytokine receptor activator of NFB ligand (RANKL), whose actions are inhibited by the soluble decoy receptor osteoprotegerin (OPG). Recent studies have shown that osteocytes are an important source of the RANKL involved in osteoclast formation. The requirement of osteocyte RANKL for osteoclast formation raises the question of how this cytokine reaches osteoclast progenitors when produced by cells embedded in the bone matrix. RANKL is initially produced as an integral- membrane protein, which can then be cleaved by proteases to yield a soluble form, both of which are able to promote bone resorption. It remains unclear whether the osteoclast formation promoted by osteocyte-derived RANKL involves the membrane-bound form, the soluble form, or both. Cortical porosity is a type of bone loss that increases with aging and glucocorticoid excess, and some studies suggest that the former is associated with increased expression of RANKL in cortical bone. However, it is unknown whether osteocytes are the source of this RANKL and whether this increase is involved in the generation of cortical porosity associated with aging or glucocorticoid excess. Some studies suggest that OPG is also produced by osteocytes and those changes in OPG production may contribute to pathological bone resorption. However, OPG is produced by many cell types and it is unclear which cells provide the OPG important for control of bone remodeling. Based on these observations, we propose the central hypothesis that osteocytes control osteoclast formation via multiple mechanisms including production of soluble RANKL and OPG and this contributes to physiological as well as pathological bone resorption. To address this hypothesis, in Aim 1 we will determine whether osteocytes control osteoclast formation via production of soluble or membrane-bound RANKL. Mice expressing a form of the RANKL protein that is resistant to proteolytic cleavage will be generated and their skeletons analyzed structurally and histologically under physiological and pathological conditions. In Aim 2, we will determine whether osteocyte-derived RANKL contributes to the cortical porosity caused by aging or glucocorticoid excess. Bone mass and structure, including cortical porosity, as well as osteoclast number, will be measured in 20-month-old mice lacking the RANKL gene in osteocytes and control littermates. The impact of glucocorticoid excess on cortical porosity will also be examined in adult mice of the same genotypes. Lastly, in Aim 3 we will determine whether osteocytes are an important source of OPG. A conditional allele of the OPG gene will be deleted from osteocytes using Dmp1-Cre and Sost-Cre transgenic mice and the skeletal phenotype compared to that of mice with germline deletion of OPG.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetic Models
-
批准号:10357774
-
项目类别:
-
资助金额:$19.68万
-
财政年份:2018
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Administrative Core
-
批准号:10117260
-
项目类别:
-
资助金额:$49.51万
-
财政年份:2018
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Center for Musculoskeletal Disease Research (CMDR)
-
批准号:10357772
-
项目类别:
-
资助金额:$227.44万
-
财政年份:2018
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Administrative Core
-
批准号:10357773
-
项目类别:
-
资助金额:$51.17万
-
财政年份:2018
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Genetic Models
-
批准号:10117261
-
项目类别:
-
资助金额:$19.04万
-
财政年份:2018
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Administrative Core
-
批准号:10495742
-
项目类别:
-
资助金额:$58.84万
-
财政年份:2018
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Center for Musculoskeletal Disease Research (CMDR)
-
批准号:10495741
-
项目类别:
-
资助金额:$229.5万
-
财政年份:2018
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Center for Musculoskeletal Disease Research (CMDR)
-
批准号:10117257
-
项目类别:
-
资助金额:$227.44万
-
财政年份:2018
-
负责人:CHARLES A O'BRIEN
-
依托单位:
RANKL and lymphocyte-mediated bone loss
-
批准号:9275307
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:CHARLES A O'BRIEN
-
依托单位:
RANKL and lymphocyte-mediated bone loss
-
批准号:8633709
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:CHARLES A O'BRIEN
-
依托单位:
RANKL and Inflammation-associated Bone Loss
-
批准号:8258635
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:CHARLES A O'BRIEN
-
依托单位:
RANKL and Inflammation-associated Bone Loss
-
批准号:7687062
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Molecular mechanisms of glucocorticoid-induced bone loss
-
批准号:10084209
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:CHARLES A O'BRIEN
-
依托单位:
RANKL and Inflammation-associated Bone Loss
-
批准号:8195622
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:CHARLES A O'BRIEN
-
依托单位:
RANKL and Inflammation-associated Bone Loss
-
批准号:7782821
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:CHARLES A O'BRIEN
-
依托单位:
TRANSGENIC MOUSE CORE
-
批准号:7094987
-
项目类别:
-
资助金额:$10.84万
-
财政年份:2006
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Osteocyte Control of Bone Remodeling
-
批准号:10442181
-
项目类别:
-
资助金额:$33.44万
-
财政年份:2003
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Osteocyte Control of Bone Remodeling
-
批准号:9236157
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2003
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Molecular Control of RANKL Gene Expression
-
批准号:7877808
-
项目类别:
-
资助金额:$31.58万
-
财政年份:2003
-
负责人:CHARLES A O'BRIEN
-
依托单位:
Molecular Control of RANKL Gene Expression
-
批准号:7663135
-
项目类别:
-
资助金额:$31.9万
-
财政年份:2003
-
负责人:CHARLES A O'BRIEN
-
依托单位:
海外基金